Composition and method for affecting obesity and related conditions

• US 8,598,150 B1
• Filed: 01/12/2009
• Issued: 12/03/2013
• Est. Priority Date: 04/02/2008
• Status: Expired due to Fees

• Current Assignee: Jonathan R. Brestoff, Thomas H. Reynolds IV
• Original Assignee: Thomas H. Reynolds IV
• Inventors: Brestoff, Jonathan R., Reynolds, Thomas H. IV
• Primary Examiner(s): CHONG, YONG SOO
• Application Number:
  US12/352,438
• Time in Patent Office: 1,786 Days
• Field of Search: 514/183
• US Class Current: 514/183
• CPC Class Codes: A23L 33/10 using additives addition of substantially indigestible substances A23L33/21
• CPC Class Codes: A23L 33/30 Dietetic or nutritional methods, e.g. for losing weight A23L33/10 takes precedence
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L

Abstract

A composition including an effective amount of a compound including manganese [III] tetrakis (4-benzoic acid) porphyrin (MnTBAP), derivatives or analogs thereof to induce a reduction in body weight of a mammal or to improve insulin sensitivity of an obese mammal. A method including introducing an effective amount of a compound including manganese [III] tetrakis (4-benzoic acid) porphyrin (MnTBAP), derivatives or analogs thereof to a mammal to induce a reduction in body weight or to induce an increase in metabolism or insulin sensitivity of the mammal.

Claims

1. A method of reducing body weight in a mammal in need thereof comprising:

delivering an effective amount of a compound comprising manganese [III] tetrakis (4-benzoic acid) porphyrin (MnTBAP), or analogs thereof to a mammal over a period of time sufficient to induce a reduction in body weight of the mammal.

2. The method of claim 1 wherein the effective amount of the compound is an amount which further enhances insulin sensitivity.

3. The method of claim 1 wherein the effective amount of the compound is from about 2.5 mg/kg of body weight to about 88 mg/kg of body weight of the mammal.

4. The method of claim 1 wherein the reduction in body weight is observed after about 15 days of delivering the effective amount of the compound to the mammal.

5. The method of claim 1 wherein the effective amount of the compound is introduced to the mammal on a daily basis.

6. The method of claim 1 wherein the effective amount of the compound is introduced to the mammal through an oral, intravenous, rectal, transmucosal, intestinal, parenteral, intrathecal, intraventricular, intraperitoneal, transdermal, intranasal or intraocular administration route.

7. The method of claim 1 wherein the effective amount of the compound is introduced to the mammal in the form of a subcutaneous capsular dispersion.

8. The method of claim 1 wherein the reduction in body weight is induced without decreasing a caloric intake of the mammal.

9. The method of claim 1 wherein the mammal expresses leptin.

10. The method of claim 1 wherein the effective amount of the compound is less than about 88 mg/kg of body weight of the mammal.